

OVERVIEW

PRESS RELEASES

EVENTS & PRESENTATIONS

CORPORATE GOVERNANCE

MANAGEMENT

BOARD OF DIRECTORS

COMMITTEE COMPOSITION

CONTACT THE BOARD

FINANCIAL INFORMATION

SEC FILINGS

ANNUAL REPORTS

QUARTERLY RESULTS

STOCK INFORMATION

HISTORIC STOCK LOOKUP

INVESTMENT CALCULATOR

ANALYST COVERAGE

INVESTOR FAQs

CONTACT US

EMAIL ALERTS



INVESTOR RELATIONS

Investor Relations

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use

in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

STOCK QUOTE


Price **Change** **High**

Apr 27, 2018 2:03 AM EDT

[VIEW DETAILS](#)

Copyright Nasdaq. Minimum 15 minutes delayed.

STOCK CHART



PRESS RELEASES

- April 23, 2018 [Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations](#)
- April 23, 2018 [Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018](#)
- April 16, 2018 [Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018](#)

EVENTS & PRESENTATIONS

[FILTER](#)

[RESET](#)

Mar 27, 2018

Melinta Therapeutics, Inc. at the Needham & Company's

17th Annual Healthcare Conference

[CLICK HERE FOR WEBCAST](#)

Mar 13,
2018

Melinta Therapeutics Q4 2017 Earnings Call

[CLICK HERE FOR WEBCAST](#)

Jan 10,
2018

Melinta Therapeutics, Inc. at the 2018 JP Morgan
Healthcare Conference Presentation

[CLICK HERE FOR WEBCAST](#)

2018 JP Morgan Healthcare Conference Presentation *1.1 MB*



梵

倭

穴